Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H18NO2.Cl.H2O |
| Molecular Weight | 213.702 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.[Cl-].COC(=O)CCC[N+](C)(C)C
InChI
InChIKey=HUCARLCBGJLGMH-UHFFFAOYSA-M
InChI=1S/C8H18NO2.ClH.H2O/c1-9(2,3)7-5-6-8(10)11-4;;/h5-7H2,1-4H3;1H;1H2/q+1;;/p-1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | HO |
| Molecular Weight | 17.0073 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C8H18NO2 |
| Molecular Weight | 160.234 |
| Charge | 1 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/16543627Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/22171995 and http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1602
Sources: http://www.ncbi.nlm.nih.gov/pubmed/16543627
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/22171995 and http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1602
Carpronium chloride is a hair growth reagent with a vasodilatory action. In vivo studies indicated that carpronium chloride achieved dilatation of vascular smooth muscle in the microcirculation of rats. FUROZIN SOLUTION 5% (active ingredient Carpronium chloride) has local vasodilating effect and hair growth stimulatory effect to improve alopecia and vitiligo. It is usually used for the prevention of hair loss, for hair growth stimulation, and in the treatment of seborrhea sicca and vitiligo vulgaris.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094109 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D01175 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | FUROZIN SOLUTION 5% Approved UseUsed for the prevention of hair loss, for hair growth stimulation, and in the treatment of seborrhea sicca and vitiligo vulgaris. |
|||
| Primary | FUROZIN SOLUTION 5% Approved UseUsed for the prevention of hair loss, for hair growth stimulation, and in the treatment of seborrhea sicca and vitiligo vulgaris. |
|||
| Primary | FUROZIN SOLUTION 5% Approved UseUsed for the prevention of hair loss, for hair growth stimulation, and in the treatment of seborrhea sicca and vitiligo vulgaris. |
Doses
| Dose | Population | Adverse events |
|---|---|---|
4500 mg single, oral Accidental dose Dose: 4500 mg Route: oral Route: single Dose: 4500 mg Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
Other AEs: Vomiting, Hot flush... Other AEs: Vomiting Sources: Hot flush Sweating Salivation Hypotension Bradycardia |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Bradycardia | 4500 mg single, oral Accidental dose Dose: 4500 mg Route: oral Route: single Dose: 4500 mg Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
|
| Hot flush | 4500 mg single, oral Accidental dose Dose: 4500 mg Route: oral Route: single Dose: 4500 mg Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
|
| Hypotension | 4500 mg single, oral Accidental dose Dose: 4500 mg Route: oral Route: single Dose: 4500 mg Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
|
| Salivation | 4500 mg single, oral Accidental dose Dose: 4500 mg Route: oral Route: single Dose: 4500 mg Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
|
| Sweating | 4500 mg single, oral Accidental dose Dose: 4500 mg Route: oral Route: single Dose: 4500 mg Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
|
| Vomiting | 4500 mg single, oral Accidental dose Dose: 4500 mg Route: oral Route: single Dose: 4500 mg Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Topical immunotherapy in alopecia areata. | 2010-01 |
|
| Effects of carpronium chloride on the microvascular blood flow in rat mesentery using intravital videomicroscopy. | 2006 |
|
| Study of active substances involved in skin dysfunction induced by crowding stress. I. Effect of crowding and isolation on some physiological variables, skin function and skin blood perfusion in hairless mice. | 2003-02 |
|
| Seventeen cases of alopecia areata: combination of SADBE topical immunotherapy with other therapies. | 2002-10 |
Patents
Sample Use Guides
For alopecia and seborrhea sicca:
In general, apply appropriate amount of the medicine to the affected area; or sprinkle the medicine on the whole scalp; twice to 3 times daily, and gently massage the head.
For vitiligo vulgaris:
In general, apply appropriate amount of the medicine to the affected area, 3 to 4 times daily.
Route of Administration:
Topical
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:29:28 GMT 2025
by
admin
on
Mon Mar 31 21:29:28 GMT 2025
|
| Record UNII |
L4864ASJ91
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
L4864ASJ91
Created by
admin on Mon Mar 31 21:29:28 GMT 2025 , Edited by admin on Mon Mar 31 21:29:28 GMT 2025
|
PRIMARY | |||
|
64675-20-3
Created by
admin on Mon Mar 31 21:29:28 GMT 2025 , Edited by admin on Mon Mar 31 21:29:28 GMT 2025
|
PRIMARY | |||
|
100000170620
Created by
admin on Mon Mar 31 21:29:28 GMT 2025 , Edited by admin on Mon Mar 31 21:29:28 GMT 2025
|
PRIMARY | |||
|
DTXSID60214949
Created by
admin on Mon Mar 31 21:29:28 GMT 2025 , Edited by admin on Mon Mar 31 21:29:28 GMT 2025
|
PRIMARY | |||
|
SUB184653
Created by
admin on Mon Mar 31 21:29:28 GMT 2025 , Edited by admin on Mon Mar 31 21:29:28 GMT 2025
|
PRIMARY | |||
|
45358895
Created by
admin on Mon Mar 31 21:29:28 GMT 2025 , Edited by admin on Mon Mar 31 21:29:28 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |